ADHD treatment in the 1990s was dominated by one drug: methylphenidate, sold most famously as Ritalin. Prescriptions for it more than doubled during the decade, driven by broadened diagnostic criteria and growing public awareness that the condition was real and treatable. But the story of 90s ADHD care is richer than a single pill. The decade saw a complete overhaul of how the disorder was defined, a fierce public debate over whether children were being overmedicated, the rise and fall of a once-popular alternative stimulant, and a landmark government-funded trial that reshaped how clinicians thought about combining medication with therapy.
A New Diagnostic Framework Changed Everything
The 1990s began with ADHD still defined by the DSM-III-R, which treated it as a single disorder centered on hyperactivity. In 1994, the American Psychiatric Association published the DSM-IV, which split ADHD into three subtypes: predominantly inattentive, predominantly hyperactive-impulsive, and combined type.1PubMed Central. Validity of DSM-IV attention deficit/hyperactivity disorder symptom dimensions and subtypes This was a significant shift. Children who daydreamed through class but never bounced off the walls could now receive a formal ADHD diagnosis for the first time under the inattentive subtype. In one county-wide sample, the inattentive type alone accounted for over 5% of children, making it the most common of the three subtypes.2PubMed. Comparison of diagnostic criteria for attention-deficit hyperactivity disorder in a county-wide sample
The practical effect was a surge in diagnosis rates. Between 1990 and 1995, the number of office visits documenting an ADHD diagnosis in school-age children jumped from roughly 950,000 to nearly 2.4 million, a more than twofold increase even after adjusting for population size.3PubMed. National trends in the prevalence of attention-deficit/hyperactivity disorder and the prescribing of methylphenidate among school-age children: 1990-1995 Hospital discharge records told a similar story: ADHD diagnosis rates nearly quadrupled over the course of the decade.4PubMed. Trends in diagnosis rates for autism and ADHD at hospital discharge in the context of other psychiatric diagnoses Critics worried this reflected cultural overreach rather than genuine medical need. Supporters pointed out that millions of children had been struggling unrecognized for years. Both camps were probably capturing part of the truth.
Ritalin and the Methylphenidate Boom
Methylphenidate had been around since the 1950s, but the 1990s turned it into a household name. Its mechanism was already well understood by that point: the drug blocks dopamine transporters in the brain, allowing more dopamine to remain available in the synaptic space between neurons, which improves focus and impulse control.5PubMed. Dopamine transporter occupancies in the human brain induced by therapeutic doses of oral methylphenidate For most of the decade, the standard version was an immediate-release tablet that lasted about three to four hours, meaning a child might need a morning dose, a lunchtime dose administered by the school nurse, and sometimes a third dose after school.
An extended-release version of methylphenidate (Ritalin-SR) had actually been developed in the early 1980s, with a generic form following in 1990.6PubMed Central. Evolution of stimulants to treat ADHD: transdermal methylphenidate In theory, one pill in the morning could replace two or three. In practice, many clinicians and families found that the early extended-release formulations were inconsistent, sometimes releasing the drug too slowly or too quickly. The truly reliable once-daily formulations (like Concerta) would not arrive until the early 2000s. So for most of the 90s, three-times-daily dosing remained common, and the lunchtime pill at school became one of the decade’s defining ADHD images.
The rate of methylphenidate prescriptions grew dramatically alongside the rise in diagnoses. The population-adjusted rate of ADHD patients prescribed methylphenidate increased roughly 2.6-fold between 1990 and 1995 alone.3PubMed. National trends in the prevalence of attention-deficit/hyperactivity disorder and the prescribing of methylphenidate among school-age children: 1990-1995 This rapid growth fueled an intense public backlash. Parents debated the ethics of medicating children at school-board meetings, talk shows aired segments questioning whether Ritalin was a chemical shortcut for bad parenting, and advocacy groups pushed back with arguments that untreated ADHD carried its own serious risks.
Dextroamphetamine and Other Stimulant Options
Ritalin was not the only stimulant game in town. Dextroamphetamine (sold as Dexedrine) had been used for ADHD since well before the 90s and was considered comparably effective to methylphenidate in head-to-head studies. Its mechanism differed slightly: rather than simply blocking dopamine reuptake, it actively triggered the release of newly made dopamine into the synapse.7PubMed. Pharmacology of methylphenidate, amphetamine enantiomers and pemoline in attention-deficit hyperactivity disorder Some children who did not respond well to methylphenidate improved on dextroamphetamine, and vice versa. Clinicians in the 90s often tried one and switched to the other if the first produced poor results or intolerable side effects. Adderall, a mixed amphetamine salt formulation, was approved in 1996 and would go on to rival Ritalin’s market share, but its full cultural impact came after the decade ended.
The Rise and Fall of Pemoline
One of the more distinctive features of 90s ADHD pharmacology was the use of pemoline, marketed as Cylert. It was appealing for a specific reason: it was a once-daily stimulant at a time when methylphenidate required multiple doses. It worked by both releasing and blocking the reuptake of dopamine, and it rarely caused the jitteriness or appetite suppression that made other stimulants unpopular with some families.7PubMed. Pharmacology of methylphenidate, amphetamine enantiomers and pemoline in attention-deficit hyperactivity disorder
The problem was the liver. Case reports began accumulating throughout the late 1980s and 1990s linking pemoline to hepatotoxicity, ranging from mild elevations in liver enzymes to outright hepatic failure. One published case described an 11-year-old who developed deep jaundice and massive liver damage.8PubMed. Hepatotoxicity due to pemoline (Cylert): a report of two cases A critical review of the literature concluded that acute hepatic failure was a real, if uncommon, risk, enough to relegate the drug to second-line status.9PubMed. Pemoline-associated hepatic failure: a critical analysis of the literature By the late 90s, the FDA required a black-box warning on pemoline, and it was eventually pulled from the U.S. market entirely in 2005. For anyone treated for ADHD in the early-to-mid-90s, though, Cylert was a real and relatively common prescription.
Non-Stimulant Medications Used Off-Label
Not every child with ADHD responded to stimulants, and some families refused them outright. In those cases, 90s-era clinicians often turned to medications originally designed for other conditions. The most common were tricyclic antidepressants, particularly desipramine and imipramine. These drugs had been around for decades as treatments for depression, but evidence suggested they also reduced ADHD symptoms. A Cochrane review of the available trial data found that tricyclics outperformed placebo substantially in children and adolescents with ADHD, with desipramine showing particular efficacy as rated by parents, teachers, and clinicians.10PubMed Central. Tricyclic antidepressants for attention deficit hyperactivity disorder (ADHD) in children and adolescents
Tricyclics came with their own baggage, however. They could cause dry mouth, constipation, and drowsiness. More worryingly, they carried cardiovascular risks, particularly cardiac arrhythmias at high doses or in overdose. Reports of sudden death in a small number of children taking desipramine circulated in the early 90s, making many pediatricians cautious about prescribing it. Clonidine, an alpha-adrenergic agonist originally used for high blood pressure, was another off-label option. It was particularly popular for children whose ADHD came with severe hyperactivity, aggression, or co-occurring tic disorders. Desipramine appeared to be more effective than clonidine at reducing core ADHD symptoms in at least one trial involving children with both ADHD and tics.10PubMed Central. Tricyclic antidepressants for attention deficit hyperactivity disorder (ADHD) in children and adolescents Still, clonidine’s sedating properties made it useful for bedtime dosing in children who could not fall asleep, a common problem with daytime stimulant use. The first FDA-approved non-stimulant specifically for ADHD, atomoxetine (Strattera), would not appear until 2002, so throughout the 90s, all non-stimulant pharmacotherapy was technically off-label.
The MTA Study and the Medication-Versus-Therapy Debate
The single most influential piece of ADHD research to come out of the 90s was the Multimodal Treatment Study of Children with ADHD, known as the MTA study. Published in 1999, it was the largest and most rigorous randomized trial of ADHD treatment ever conducted at that time. The study enrolled nearly 600 children aged 7 to 9 and randomly assigned them to one of four treatment arms: carefully managed medication alone, intensive behavioral therapy alone, a combination of both, or routine community care (where families sought whatever treatment they could find on their own).
The results shaped clinical thinking for years. All four groups improved, but children receiving carefully managed medication, whether alone or combined with behavioral therapy, showed significantly greater improvement in core ADHD symptoms than those receiving behavioral therapy alone or community care.11PubMed. A 14-month randomized clinical trial of treatment strategies for attention-deficit/hyperactivity disorder For the headline ADHD symptoms of inattention and hyperactivity, adding behavioral therapy to medication did not produce measurably better results than medication alone. But the combined approach did outperform medication-only on several secondary outcomes, including oppositional behavior, anxiety, social skills, and parent-child relationships.11PubMed. A 14-month randomized clinical trial of treatment strategies for attention-deficit/hyperactivity disorder
This created a nuanced message that was often oversimplified in the press. Headlines declared that medication had “won” the medication-vs-therapy debate, which was a misreading. What the study actually showed was that medication managed the core symptoms more effectively, but that behavioral interventions added real value in areas of life that go beyond attention and impulse control, areas like getting along with parents and peers. The study also contained a subtle but damning finding about community care: about two-thirds of the children in the community-care group ended up on medication through their own doctors, yet their outcomes were significantly worse than those in the study’s medication-management arm. The difference was not whether they received medication, but how carefully that medication was monitored and adjusted.
Behavioral and Parent Training Approaches
Even before the MTA study results came in, behavioral interventions were a recognized part of the 90s ADHD toolkit. Parent training programs taught families to use consistent reward systems, structured routines, and clear consequences to manage disruptive behavior. Studies from the early 90s found that a roughly ten-week behavioral training program for parents produced reductions in parenting stress and improvements in parenting confidence, alongside parent-reported decreases in ADHD symptom severity.12PubMed. Parent training for attention-deficit hyperactivity disorder: its impact on parent functioning These gains held at two-month follow-up. Case studies with preschool-aged children found similar benefits, including improvements in parent-child relationships and targeted behavior problems.13Journal of Behavior Therapy and Experimental Psychiatry. The effects of behavioral parent training on families with young hyperactive children
The limitation was access. Behavioral parent training required specialized therapists, multiple sessions, and family commitment over weeks or months. In the 90s, insurance coverage for such programs was spotty, and availability outside major metropolitan areas was limited. Many families simply could not get it. Medication, by contrast, could be prescribed in a single office visit. The structural imbalance between how easy it was to get a Ritalin prescription and how hard it was to access quality behavioral therapy partially explains why the decade became so medication-centric.
School Accommodations and Section 504
The 90s also saw important changes in how schools responded to ADHD. The U.S. Department of Education issued a policy memorandum in 1991 clarifying that children with ADHD could qualify for special accommodations under Section 504 of the Rehabilitation Act or under the Individuals with Disabilities Education Act (IDEA), depending on the severity of their impairment. This opened the door for classroom supports like extended test time, preferential seating, and modified homework assignments.
Testing accommodations, particularly extended time, became the most common school-based response to ADHD. Yet the evidence base for these accommodations has remained surprisingly thin even decades later. A systematic review of the research found that most accommodations lack experimental studies demonstrating specific benefits for students with ADHD. An exception was read-aloud accommodations for younger students, which did show measurable benefits in randomized experiments.14Elsevier / PubMed Central (J Am Acad Child Adolesc Psychiatry). Systematic Review: Educational Accommodations for Children and Adolescents With Attention-Deficit/Hyperactivity Disorder Students and their families often expressed ambivalence about the process, and the accommodations could feel more like bureaucratic gestures than genuinely targeted support.
Who Got Missed in the 90s
The diagnostic expansion of the 1990s was unevenly distributed. Girls, in particular, were systematically underdiagnosed. Because the classic image of ADHD was a hyperactive boy disrupting class, girls whose symptoms presented as quiet inattention flew under the radar. Clinicians had a low index of suspicion for ADHD in girls, partly because inattentiveness was considered “subthreshold” compared to hyperactivity and impulsivity.15PubMed Central. A review of attention-deficit/hyperactivity disorder in women and girls: uncovering this hidden diagnosis Girls also tended to develop coping strategies that masked their difficulties, and their common comorbidities of anxiety and depression often led clinicians to diagnose the wrong condition entirely.15PubMed Central. A review of attention-deficit/hyperactivity disorder in women and girls: uncovering this hidden diagnosis
Adults were another overlooked group. ADHD had been considered almost exclusively a childhood condition through the 1970s and 80s. It was only during the 1990s that “ADHD adults” emerged as a recognized category.16Social Problems. From Hyperactive Children to ADHD Adults: Observations on the Expansion of Medical Categories Pioneering neuroimaging work published in 1990 had shown that adults who had been hyperactive as children displayed measurably lower cerebral glucose metabolism than controls, with the largest reductions concentrated in the prefrontal cortex, the brain region most associated with executive function.17PubMed. Cerebral glucose metabolism in adults with hyperactivity of childhood onset This finding gave biological credibility to the idea that ADHD did not simply vanish at puberty. Still, adult ADHD treatment infrastructure barely existed in the 90s. Most psychiatrists who treated the condition worked with children, and adult patients often struggled to find clinicians willing to evaluate or treat them.
Alternative and Complementary Treatments
The 90s also saw significant interest in non-pharmaceutical approaches beyond behavioral therapy. Elimination diets, particularly the oligoantigenic or “few-foods” diet, had accumulated what one review called “convincing double-blind evidence of efficacy” for a properly selected subgroup of children.18Journal of Attention Disorders. Treatment alternatives for Attention-Deficit! Hyperactivity Disorder (ADHD) The idea was that certain food additives or allergens worsened ADHD symptoms in some children, and removing them from the diet could reduce hyperactivity. It worked for a minority, but identifying which children would respond required weeks of restrictive eating followed by careful reintroduction, making it impractical for most families.
EEG biofeedback (also called neurofeedback) generated excitement as an emerging technique. The approach trained children to modify their own brainwave patterns, and early pilot data looked promising. Mineral supplementation with iron and magnesium, meditation, massage therapy, and even vestibular stimulation exercises all had preliminary positive data from small, sometimes reasonably controlled studies.19PubMed. Alternative treatments for adults with attention-deficit hyperactivity disorder (ADHD) None of these alternatives had the depth of evidence supporting stimulant medication, and mainstream clinical guidelines continued to position them as supplements to, rather than replacements for, conventional treatment. For families who were resistant to medication, though, they represented something more than wishful thinking.
Growth Concerns and Safety Monitoring
One of the recurring worries for parents throughout the 90s was whether stimulant medication would stunt their child’s growth. The concern was not baseless: methylphenidate can suppress appetite, and children on it sometimes ate less. The scientific debate had been ongoing for decades. By the late 90s, the consensus from more recent studies was that effects on final adult height were only slight, though the question was far from fully resolved.20PubMed. Methylphenidate-related growth impairment Severe growth deficits attributed to methylphenidate were rare and typically linked to gastrointestinal side effects that interfered with eating. Pediatricians commonly tracked height and weight on growth charts at each visit, and “drug holidays” over summer vacations were a popular strategy to let children catch up on calories and growth during medication-free months.
Beyond growth, the common side effects families dealt with included insomnia, decreased appetite, stomachaches, and occasionally increased anxiety or irritability. The short duration of immediate-release methylphenidate meant that side effects tended to peak and fade within hours. Rebound effects, where a child became noticeably more hyperactive or emotional as the medication wore off in the late afternoon, were a frequent complaint that clinicians managed by adjusting dose timing or adding a small late-afternoon dose.
ADHD Treatment as a Largely American Phenomenon
It is worth stepping back to note how geographically concentrated the 90s ADHD treatment landscape was. ADHD diagnosis and stimulant prescribing were primarily a North American practice until the late 1990s. European countries had markedly different attitudes toward the condition. France emphasized psychodynamic approaches over medication. The UK had lower diagnosis rates and more conservative prescribing norms. Germany, Italy, and Brazil were just beginning to grapple with the disorder as a medical category by the end of the decade.21PubMed. The impending globalization of ADHD: notes on the expansion and growth of a medicalized disorder By the early 2000s, international adoption of ADHD diagnosis and treatment accelerated, but the 90s remain a distinctly American chapter in the disorder’s history. The diagnosed prevalence among U.S. children climbed from about 6% at the start of this period to over 10% within two decades.22JAMA Network Open. Twenty-Year Trends in Diagnosed Attention-Deficit/Hyperactivity Disorder Among US Children and Adolescents, 1997-2016 Much of that trajectory was set in motion by the diagnostic, pharmacological, and cultural shifts of the 1990s.